Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2013, Article ID 265259, 10 pages
http://dx.doi.org/10.1155/2013/265259
Research Article

Diffusion Tensor Imaging in NAWM and NADGM in MS and CIS: Association with Candidate Biomarkers in Sera

1Neuroimmunology Unit, Medical School, University of Tampere, 33520 Tampere, Finland
2Department of Neurology, Tampere University Hospital, 33520 Tampere, Finland
3Department of Radiology, Medical Imaging Centre, Tampere University Hospital, 33520 Tampere, Finland
4Department of Neurology, Seinäjoki Central Hospital, 60220 Seinäjoki, Finland
5Science Center, Pirkanmaa Hospital District and School of Health Sciences, University of Tampere, 33520 Tampere, Finland
6Department of Electronics and Communications Engineering, Tampere University of Technology, 33520 Tampere, Finland

Received 29 July 2013; Revised 9 October 2013; Accepted 9 October 2013

Academic Editor: Sten Fredrikson

Copyright © 2013 Renuka Natarajan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. F. Wu and E. Alvarez, “The immunopathophysiology of multiple sclerosis,” Neurologic Clinics, vol. 29, no. 2, pp. 257–278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Comabella and K. Vandenbroeck, “Pharmacogenomics and multiple sclerosis: moving toward individualized medicine,” Current Neurology and Neuroscience Reports, vol. 11, no. 5, pp. 484–491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. U. Ziemann, M. Wahl, E. Hattingen, and H. Tumani, “Development of biomarkers for multiple sclerosis as a neurodegenerative disorder,” Progress in Neurobiology, vol. 95, no. 4, pp. 670–685, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Filippi and F. Agosta, “Imaging biomarkers in multiple sclerosis,” Journal of Magnetic Resonance Imaging, vol. 31, no. 4, pp. 770–788, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Cohen, S. C. Reingold, C. H. Polman, and J. S. Wolinsky, “Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects,” The Lancet Neurology, vol. 11, no. 5, pp. 467–476, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Kutzelnigg, C. F. Lucchinetti, C. Stadelmann et al., “Cortical demyelination and diffuse white matter injury in multiple sclerosis,” Brain, vol. 128, no. 11, pp. 2705–2712, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Filippi, M. Absinta, and M. A. Rocca, “Future MRI tools in multiple sclerosis,” Journal of the Neurological Sciences, vol. 331, no. 1, pp. 14–18, 2013. View at Publisher · View at Google Scholar
  8. M. Rovaris, F. Agosta, E. Pagani, and M. Filippi, “Diffusion tensor MR imaging,” Neuroimaging Clinics of North America, vol. 19, no. 1, pp. 37–43, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Vrenken, J. J. G. Geurts, D. L. Knol et al., “Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis,” American Journal of Neuroradiology, vol. 27, no. 9, pp. 2005–2011, 2006. View at Google Scholar · View at Scopus
  10. S. D. Roosendaal, J. J. G. Geurts, H. Vrenken et al., “Regional DTI differences in multiple sclerosis patients,” NeuroImage, vol. 44, no. 4, pp. 1397–1403, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Cercignani, M. Bozzali, G. Iannucci, G. Comi, and M. Filippi, “Intra-voxel and inter-voxel coherence in patients with multiple sclerosis assessed using diffusion tensor MRI,” Journal of Neurology, vol. 249, no. 7, pp. 875–883, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Poloni, A. Minagar, E. M. Haacke, and R. Zivadinov, “Recent developments in imaging of multiple sclerosis,” Neurologist, vol. 17, no. 4, pp. 185–204, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. R. G. Henry, M. Shieh, B. Amirbekian, S. Chung, D. T. Okuda, and D. Pelletier, “Connecting white matter injury and thalamic atrophy in clinically isolated syndromes,” Journal of the Neurological Sciences, vol. 282, no. 1-2, pp. 61–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Tao, S. Datta, R. He, F. Nelson, J. S. Wolinsky, and P. A. Narayana, “Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry,” Journal of the Neurological Sciences, vol. 282, no. 1-2, pp. 39–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Battaglini, A. Giorgio, M. L. Stromillo et al., “Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis,” Journal of the Neurological Sciences, vol. 282, no. 1-2, pp. 55–60, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. C. M. Griffin, D. T. Chard, O. Ciccarelli et al., “Diffusion tensor imaging in early relapsing-remitting multiple sclerosis,” Multiple Sclerosis, vol. 7, no. 5, pp. 290–297, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. K. M. Hasan, R. K. Gupta, R. M. Santos, J. S. Wolinsky, and P. A. Narayana, “Diffusion tensor fractional anisotropy of the normal-appearing seven segments of the corpus callosum in healthy adults and relapsing-remitting multiple sclerosis patients,” Journal of Magnetic Resonance Imaging, vol. 21, no. 6, pp. 735–743, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Wilson, C. R. Tench, P. S. Morgan, and L. D. Blumhardt, “Pyramidal tract mapping by diffusion tensor magnetic resonance imaging in multiple sclerosis: improving correlations with disability,” Journal of Neurology Neurosurgery and Psychiatry, vol. 74, no. 2, pp. 203–207, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Cader, H. Johansen-Berg, M. Wylezinska et al., “Discordant white matter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis,” NeuroImage, vol. 36, no. 1, pp. 19–27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. O. Ciccarelli, D. J. Werring, C. A. M. Wheeler-Kingshott et al., “Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations,” Neurology, vol. 56, no. 7, pp. 926–933, 2001. View at Google Scholar · View at Scopus
  21. X. Lin, C. R. Tench, P. S. Morgan, G. Niepel, and C. S. Constantinescu, “'Importance sampling' in MS: use of diffusion tensor tractography to quantify pathology related to specific impairment,” Journal of the Neurological Sciences, vol. 237, no. 1-2, pp. 13–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. O. Ciccarelli, C. A. Wheeler-Kingshott, M. A. McLean et al., “Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis,” Brain, vol. 130, no. 8, pp. 2220–2231, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Giorgio, J. Palace, H. Johansen-Berg et al., “Relationships of brain white matter microstructure with clinical and MR measures in relapsing-remitting multiple sclerosis,” Journal of Magnetic Resonance Imaging, vol. 31, no. 2, pp. 309–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Derfuss, “Personalized medicine in multiple sclerosis: hope or reality?” BMC Medicine, vol. 10, article 116, 2012. View at Publisher · View at Google Scholar
  25. V. Pravica, M. Markovic, M. Cupic et al., “Multiple sclerosis: individualized disease susceptibility and therapy response,” Biomarkers in Medicine, vol. 7, no. 1, pp. 59–71, 2013. View at Publisher · View at Google Scholar
  26. S. Hagman, M. Raunio, M. Rossi, P. Dastidar, and I. Elovaara, “Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study,” Journal of Neuroimmunology, vol. 234, no. 1-2, pp. 141–147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Ukkonen, X. Wu, B. Reipert, P. Dastidar, and I. Elovaara, “Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis,” Multiple Sclerosis, vol. 13, no. 6, pp. 701–707, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Tumani, H.-P. Hartung, B. Hemmer et al., “Cerebrospinal fluid biomarkers in multiple sclerosis,” Neurobiology of Disease, vol. 35, no. 2, pp. 117–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Krumbholz, H. Faber, F. Steinmeyer et al., “Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity,” Brain, vol. 131, no. 6, pp. 1455–1463, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Kraus, B. S. Kuehne, J. Tofighi et al., “Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis,” Acta Neurologica Scandinavica, vol. 105, no. 4, pp. 300–308, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Giovannoni, D. H. Miller, N. A. Losseff et al., “Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis,” Journal of Neurology, vol. 248, no. 6, pp. 487–495, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald criteria’,” Annals of Neurology, vol. 58, no. 6, pp. 840–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Google Scholar · View at Scopus
  34. U. Hakulinen, A. Brander, P. Ryymin et al., “Repeatability and variation of region-of-interest methods using quantitative diffusion tensor MR imaging of the brain,” BMC Medical Imaging, vol. 12, article 30, 2012. View at Publisher · View at Google Scholar
  35. S. Rinta, H. Kuusisto, M. Raunio et al., “Apoptosis-related molecules in blood in multiple sclerosis,” Journal of Neuroimmunology, vol. 205, no. 1-2, pp. 135–141, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Tian, T. Zhu, J. Zhong et al., “Progressive decline in fractional anisotropy on serial DTI examinations of the corpus callosum: a putative marker of disease activity and progression in SPMS,” Neuroradiology, vol. 54, no. 4, pp. 287–297, 2012. View at Publisher · View at Google Scholar
  37. T. Sigal, M. Shmuel, D. Mark, H. Gil, and A. Anat, “Diffusion tensor imaging of corpus callosum integrity in multiple sclerosis: correlation with disease variables,” Journal of Neuroimaging, vol. 22, no. 1, pp. 33–37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Vrenken, P. J. W. Pouwels, J. J. G. Geurts et al., “Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration,” Journal of Magnetic Resonance Imaging, vol. 23, no. 5, pp. 628–636, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Preziosa, M. A. Rocca, S. Mesaros et al., “Intrinsic damage to the major white matter tracts in patients with different clinical phenotypes of multiple sclerosis: a voxelwise diffusion-tensor MR study,” Radiology, vol. 260, no. 2, pp. 541–550, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. C. S. Yu, F. C. Lin, Y. Liu, Y. Duan, H. Lei, and K. C. Li, “Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis,” European Journal of Radiology, vol. 68, no. 2, pp. 328–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Gallo, M. Rovaris, R. Riva et al., “Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis,” Archives of Neurology, vol. 62, no. 5, pp. 803–808, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Raz, M. Cercignani, E. Sbardella et al., “Clinically isolated syndrome suggestive of multiple sclerosis: voxelwise regional investigation of white and gray matter,” Radiology, vol. 254, no. 1, pp. 227–234, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Hannoun, M. Bagory, F. Durand-Dubief et al., “Correlation of diffusion and metabolic alterations in different clinical forms of multiple sclerosis,” PLoS One, vol. 7, no. 3, Article ID e32525, 2012. View at Publisher · View at Google Scholar
  44. P. Tortorella, M. A. Rocca, D. M. Mezzapesa et al., “MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis,” Journal of Neurology, vol. 253, no. 7, pp. 903–907, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Bramow, J. M. Frischer, H. Lassmann et al., “Demyelination versus remyelination in progressive multiple sclerosis,” Brain, vol. 133, no. 10, pp. 2983–2998, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Onu, A. Roceanu, U. Sboto-Frankenstein et al., “Diffusion abnormality maps in demyelinating disease: correlations with clinical scores,” European Journal of Radiology, vol. 81, no. 3, pp. e386–e391, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Tovar-Moll, I. E. Evangelou, A. W. Chiu et al., “Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T,” American Journal of Neuroradiology, vol. 30, no. 7, pp. 1380–1386, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Hannoun, F. Durand-Dubief, C. Confavreux et al., “Diffusion tensor-MRI evidence for extra-axonal neuronal degeneration in caudate and thalamic nuclei of patients with multiple sclerosis,” American Journal of Neuroradiology, vol. 33, no. 7, pp. 1363–1368, 2012. View at Publisher · View at Google Scholar
  49. M. Calabrese, F. Rinaldi, D. Seppi et al., “Cortical diffusion-tensor imaging abnormalities in multiple sclerosis: a 3-year longitudinal study,” Radiology, vol. 261, no. 3, pp. 891–898, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Shiee, P. L. Bazin, K. M. Zackowski et al., “Revisiting brain atrophy and its relationship to disability in multiple sclerosis,” PLoS One, vol. 7, no. 5, Article ID e37049, 2012. View at Publisher · View at Google Scholar
  51. S. Mesaros, M. A. Rocca, E. Pagani et al., “Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years,” American Journal of Neuroradiology, vol. 32, no. 6, pp. 1016–1020, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. D. Horakova, T. Kalincik, J. Blahova Dusankova, and O. Dolezal, “Clinical correlates of grey matter pathology in multiple sclerosis,” BMC Neurology, vol. 12, article 10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Lassmann, W. Brück, and C. F. Lucchinetti, “The immunopathology of multiple sclerosis: an overview,” Brain Pathology, vol. 17, no. 2, pp. 210–218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Sospedra and R. Martin, “Immunology of multiple sclerosis,” Annual Review of Immunology, vol. 23, pp. 683–747, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Rajasekharan and A. Bar-Or, “From bench to MS bedside: challenges translating biomarker discovery to clinical practice,” Journal of Neuroimmunology, vol. 248, no. 1, pp. 66–72, 2012. View at Publisher · View at Google Scholar
  56. M. Comabella and M. K. Racke, “New technologies for biomarker discovery in multiple sclerosis,” Journal of Neuroimmunology, vol. 248, no. 1, p. 1, 2012. View at Publisher · View at Google Scholar
  57. A. P. Kithcart, G. M. Cox, T. Sielecki et al., “A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease,” The FASEB Journal, vol. 24, no. 11, pp. 4459–4466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. M. H. Holtmann and M. F. Neurath, “Differential TNF-signaling in chronic inflammatory disorders,” Current Molecular Medicine, vol. 4, no. 4, pp. 439–444, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Zipp, “Apoptosis in multiple sclerosis,” Cell and Tissue Research, vol. 301, no. 1, pp. 163–171, 2000. View at Google Scholar · View at Scopus